TTK Healthcare Share Price

NSE
TTKHLTCARE •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in TTK Healthcare Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
52W Low on Nov 24, 2023
-11.7
TTM PE Ratio
Above industry Median
25.6
Price to Book Ratio
Below industry Median
2.1
Dividend yield 1yr %
Below industry Median
0.7
TTM PEG Ratio
PEG TTM is less than 1
0.8

TTK Healthcare Ltd shareholding Pattern

Promoter
74.6%
Foreign Institutions
1.9%
Domestic Institutions
1.1%
Public
22.4%
Promoter
74.6%
Foreign Institutions
1.9%
Domestic Institutions
1.1%
Public
22.4%
Promoter
74.6%
Foreign Institutions
1.8%
Domestic Institutions
1.1%
Public
22.4%
Promoter
74.6%
Foreign Institutions
1.8%
Mutual Funds
2%
Domestic Institutions
3.1%
Public
20.5%
Promoter
74.6%
Foreign Institutions
1.8%
Mutual Funds
2.1%
Domestic Institutions
3.2%
Public
20.4%
Promoter
74.6%
Foreign Institutions
2.4%
Mutual Funds
2.1%
Domestic Institutions
3.3%
Public
19.8%

TTK Healthcare Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
1
Bearish Moving Averages
15
5Day EMA
1,451.90
10Day EMA
1,470.50
12Day EMA
1,478.50
20Day EMA
1,507.30
26Day EMA
1,524.60
50Day EMA
1,561.10
100Day EMA
1,565.60
200Day EMA
1,518.70
5Day SMA
1,438.20
10Day SMA
1,476.20
20Day SMA
1,508.10
30Day SMA
1,555.30
50Day SMA
1,607.50
100Day SMA
1,579.20
150Day SMA
1,550.30
200Day SMA
1,542.20
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
2329 Rs
2667 Rs
Week Rs
2677 Rs
3722 Rs
Month Rs
4674 Rs
6770 Rs
Resistance & Support
1,451.15
Pivot
Resistance
First Resistance
1,462.30
Second Resistance
1,476.25
Third Resistance
1,487.40
Support
First Support
1,437.20
Second support
1,426.05
Third Support
1,412.10
Relative Strength Index
35.18
Money Flow Index
22.17
MACD
-46.13
MACD Signal
-41.44
Average True Range
44.05
Average Directional Index
18.08
Rate of Change (21)
-10.90
Rate of Change (125)
-2.25

TTK Healthcare Ltd Company background

Founded in: 1958
TTK Healthcare Limited, a TTK Group Company was incorporated in May 1958 as Orient Pharma and later renamed as TTK Pharma in Nov 81. The Company is the owner of famous Woodwards Gripewater brand. The Company operate into five main Strategic Business Units namely, Pharmaceuticals, Consumer Products, Medical Devices, Foods and Protective Devices divisions. It is engaged into Animal Welfare Products, Consumer Products, Medical Devices, Protective Devices and Foods Businesses. In 1992, the company came out with a rights issue at a premium of Rs 35 aggregating Rs 5.81 cr to finance longterm working capital needs, normal capital expenditure, and product promotion. Products of TTK Healthcare include cardiac care systems, blood management systems, renal care systems, hospital accessories, antibiotics, Woodwards gripe water, animal medicines, etc. It also has a consumer products and food division manufacturing kiwi shoe polishes, snacks, etc. The company has collaborations with a number of foreign corporations such as London International, KaliChemi, Germany HatuICO, Spain Nicholas Kiwi, US, etc. The products of the company are exported to the UK, Egypt, the US, Germany, Singapore, Malaysia, Carribean countries, etc.The Pallavaram plant of the company has been accredited with the ISO 14002 certification by the Bureau of Indian Standards. Also, one of the group companies, TT Maps and Publications was merged with TTK Pharma in 1993.The company faced some rough weather in Jul.95 when the MRTPC ordered an inquiry against it for allegedly directing its wholesalers to keep a minimum stock of the companys products and defining their area of operations. During 199697, the company has tied up with M/s Mentholatum India Pvt Ltd.During the year 19992000, as a part of the restructuring programme, the paper divison of the company has been disposed off and the merger of TTK Biomed has been approved by the Honble High Court Of Madras with retrospective effect from July 1, 1999.In 200001, the company has vacated the bulk drug business segment by disposing of the Bulk Drugs Formulations facility at Hyderabad.The High Court, Madras has approved the scheme of amlagamation between TTK Medical Devices Ltd. and the company.During the financial year 200304,the Heart Valve division of the company has been awarded ISO 90012000 Certification by RWTUV,Germany.Under the Ethical Products Division, Company launched three new products viz., OFORDLB (Ofloxcacin with Omidazole Lactobacillus a broad spectrum antimicrobial) NUROBEST (Methylcobalamin with Alpha Lipoic Acid to prevent and treat neuropathy) and OSSOPANALFA (Calcium with Alfacalcidol to prevent and treat Osteoporosis) DURING 2004. During November 2004, a Strategic Partner was inducted into M/s.TTK Healthcare Services Private Limited, the Subsidiary of Company to infuse further capital into this entity. Consequent to allotment of shares to the said Strategic Partners by TTK Healthcare Services Private Limited, the Shareholding of Company in the said Subsidiary reduced from 56.33% to 35.06% during the year 200405 and consequently, TTK Healthcare Services Private Limited ceased to be the Subsidiary of Company.During 2005, the Company launched OSSOGEMS (Chewable Milk Qalcium) and relaunched ARTHRID (an antiArthritis Formulation). Under the Animal Welfare Division, three new products viz., LYSETIK (Deltamethrin), ENROBEST (Enrofloxacin) and TT ZYME (Cocktail Enzyme) have been recently launched. To bring about an enhanced focus on the HerbalProducts Segment, Company launched a New Marketing Division VENTURA. It expanded the Animal Welfare Division operations in Punjab and Uttar Pradesh.The Company launched Moisturizer under the Brand Eva Nourish during the year 2006. It launched a range of Pain Management Products under the brand name DOLOBEST and three new products viz., CALCITRIOL (a Calcium Supplement), RABULCERD (an AntiUlcerant) and LEVOCOLD (an Anticold preparation) under the Ethical Products Division. It launched 3 new products viz., PROTOGENG (Protein Supplement). DELiVERA (Moisturizing Cream) and CLIMACTER (forMenopausal Symptoms) under Ventura Division. It launched quality soap for babies under the brand Woodwards Baby Bath in two variants in Tamil Nadu and Andhra Pradesh under the Consumer Products Division. It launched BLOX (Toxin Binder), TEFROLI FORTE PET (Liver Tonic) and TTCEF (Cephalosporin Injection) under the Animal Welfare business division.During the year 2007, the Company launched three new products viz., LYCOQ (Male Infertility Formulation), ARTHRID OIL (AntiArthritis Formulation) and UTRONORM FORTE (Fortified Version of Poly Herbal Uterine Tonic) under the Ventura Division launched a new product viz., IMMULAR (Herbal Immuno Modulator) under the Animal Welfare Division. It launched a Moisturizer and a Lip Balm under the EVA brand. During year 2008, the Company launched five new products viz., LycoprostSP (for treating prostate enlargement) DoloutP (pain killer) Krease (pancreatin enzyme) Elcarim IQ (IQ enhancer) and Calzibor (calcium supplement) under the Ventura Division. Animal Welfare Division launched four new products viz., Prophytase (enzyme preparation) Rumibest (digestive powder) Lavitone Liquid LavitoneH Injection (vitamin supplement) and MelobestP (antiinflammatory / analgesic Injection). The business undertaking of Medical Devices Division at Waluj was sold during the year. During year 2009, the Company launched four formulations viz., LR Zin, LR Zin Forte, CCQ 25 and CCQ 50 into the Ventura Division. Melobest Inj. and Melobest Bolus (Antiinflammatory/Analgesic) were added to the range into the Animal Welfare Division. Fantasy Talc was added to the talcum powder range. Further, EVA Sun Shield got launched under the skin care category. Under the Good Home Range, Room Spray and new variants of Scrubbers such as Large, 2inone, Xtra Tough, etc., were introduced into the Consumer Products Division. In 2010, PBiotic (a combination of Pre Probiotic), Urofit (an alkalizer for managing renal stones), Ossopan BMD (a mineral fortified calcium preparation for the treatment of osteoporosis) and Folibest DHA (folic acid and iodine based supplement) were launched into the Ethical Products Division. Company enhanced its presence in the antiinfertility segment with the launch of three new formulations viz., Aromatin (Letrozole), ChromiNacA (a combination of Chromium Picolinate and NAcetyl Cysteine) and CarniQ (a combination of LCarnitine and Coenzyme Q10). Increlac (Herbal Galactagogue), Gestaforte Plus Bolus (Fertility Promoter), Blox OA (Toxin Binder with organic acids) were the new products added to the range into the Animal Welfare Division Buisness during the year 200910. The Company acquired the Manufacturing Facility for Orthopaedic Implants including Total Knee Replacement System from Invicta Meditek Limited in July 2009 by getting into the Ortho Segment. The Pellet (Pappad) manufacturing line imported from M/s Fen, Italy was erected and commissioned in November, 2010 into the Foods Business. The Lip Balm was introduced into the Consumer Products Division during the year 201011. In November 2012, TTK Protective Devices Limited launched a new brand of Condom Skore into the Consumer Products Business division. A small manufacturing facility was set up for manufacturing Instrumentation Sets at Chromepet, Chennai into the Ortho Division. The Fen make Pellet (Pappad) Manufacturing line acquired from M/s McFills, Ahmedabad was commissioned and both the Fen Lines and the old refurbished Pavan Lines started working at full capacity into the Foods Business Division. Thereafter, the Company launched retail packs of Readytofry Snack Pellets (Pappads) in Andhra Pradesh, during First Quarter of 201314.The Company embarked upon growing projects for Foods Business including the new manufacturing facility set up in Jaipur in 201314.It introduced a number of products in AntiUlcerant, Respiratory, Infertility and Gynaecology segments to consolidate into these therapeutic segments of Ethical Products Division (EPD) Ventura Division during 201516.During the year 201617, Company introduced a couple of line extensions under Ossopan brand to strengthen the Calcium Segment. During the year 201617, ompany made an investment of Rs.3.40 lakhs in M/s Renew Wind Power (AP) Private Limited, in connection with purchase of wind power, by way of subscription to the issue of 3,400 Equity Shares of face value of Rs.10 each at a price of Rs.100 per Equity Share. Subsequently, 2,500 Equity Shares were transferred to M/s Renew Wind Power (Karnataka Three) Private Limited at a price of Rs.100 each, thus holding the balance 900 Equity Shares of Rs.10 each (Rs.0.90 lakhs) as on 31st March, 2017.During year 201718, TTK Protective Devices Limited and its Wholly Owned Subsidiary TSL Techno Services Limited was merged with the Company through the Scheme of Amalgamation dated 15th December, 2017, where the Appointed Date of the Scheme was 1st April, 2012. Consequent to the above, the erstwhile TTK Protective Devices Limited became a Division of Company and for operational convenience, which was named as Protective Devices Division. The development and testing of Cementless Hip Implant was commissioned into the Ortho Division during the year 201819. During the year 201920, the Company had bifurcated the Ventura Division into (i) Ventura Gynaec and (ii) Ventura Fertility. Jessica QF (a novel pregnancy supplement), Sensipreg SR (progesterone), Erafos (Fosfomycin) and Pufer (a Haematinic) was newly launched in 201920. The packaging of the EVA Deodorant was fully revamped with a two tone colour scheme and also complete change in the graphics of the pack. This new pack was launched in March, 2019. Skore brand was extended with pleasure aids like Orgasmic Gel for women, Vibrating Rings as well as Pheromone Activating Spray for men.During the year 202021, the Company launched products such as Bilbay M (Antihistamine) and Ossopan Active (Immunity booster) into the Respiratory and GP/CP segments, respectively.During the year 202122, the Human Pharma Division (Undertaking) of Company was transferred, as a going concern, on a slump sale basis, for a consideration of Rs.805 crores to M/s BSV Pharma Private Limited (BSV), with effect from 9th May, 2022. Two new products, viz., Chirocyst DS and PCO 360 were launched under Ventura Division during 202122. The launch of Sponge Wipes and Ultrascrubbers widened the portfolio into the Good Home Business division during the year. During the year 202223, Company launched the improved Skore 4.0 version with a new packaging and also added lubricants to the range into Protective Devices Business. It recommenced manufacturing operations at the Virudhunagar facility.
Read More

TTK Healthcare Ltd FAQs

TTK Healthcare Ltd shares are currently priced at 1448.35 on NSE and 1445.4 on BSE as of 11/19/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of TTK Healthcare Ltd [TTKHLTCARE] share was 10.78. The TTK Healthcare Ltd [TTKHLTCARE] share hit a 1-year low of Rs. 1290.5 and a 1-year high of Rs. 1893.95.

The market cap of TTK Healthcare Ltd is Rs. 2046.57 Cr. as of 11/19/2024 12:00:00 AM.

The PE ratios of TTK Healthcare Ltd is 31.57 as of 11/19/2024 12:00:00 AM.

The PB ratios of TTK Healthcare Ltd is 1.97 as of 11/19/2024 12:00:00 AM

You can easily buy TTK Healthcare Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -